An Open-Label, Multi-Centre, Randomised, Switch Study to Evaluate the Virological Efficacy Over 96 Weeks Of 2-Drug Therapy With DTG/RPV FDC in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTIs Resistance Mutation K103N

HIV-1-infection Clinical Trial

— WISARD  

Official title:

An Open-Label, Multi-Centre, Randomised, Switch Study to Evaluate the Virological Efficacy Over 96 Weeks Of 2-Drug Therapy With DTG/RPV FDC in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTIs Resistance Mutation K103N

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05349838
• Other study ID #: NEAT 33
• Secondary ID: 2017-004040-38
• Status: Completed
• Phase: Phase 3
• Start date: November 5, 2018
• Est. completion date: October 27, 2022

Study information

• Verified date: December 2022
• Source: NEAT ID Foundation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

HIV-1 infected subjects that experience virological failure while on non nucleoside reverse-transcriptase inhibitors (NNRTIs), including those with the K103N mutation, are usually switched to a boosted PI-based regimen or other antiretroviral (ARV) combinations. The same is true for subjects who need to start antiretroviral therapy and have acquired virus that is already resistant to antiretrovirals. These "second line" combinations are often associated with numerous issues that can have a potential impact on the quality of life (QoL) of these patients. Therefore a simpler and better tolerated alternative second line treatment option would be a useful tool for the clinical management of these patients. The aim of this study is to assess the efficacy and tolerability of a dual combined therapy of Dolutegravir (DTG) 50 mg OD + Rilpivirine (RPV) 25 mg OD in virologically suppressed participants with previous virological failure with NNRTIs and having the clinically significant mutation K103N. The secondary objective of the study is to assess whether a simplification of the treatment in terms of pill burden, long term metabolic toxicity and potential for drug interactions improves the QOL of the participants. The study will also evaluate DTG & RPV concentrations in the blood plus changes in cell associated virus. In order to compare the first line treatment (boosted PI and/or other antiretroviral combinations) and the DTG+RPV combination, two thirds of study participants will be switched to DTG+RPV immediately and receive DTG+RPV for 96 weeks. The other third will be switched after 48 weeks of continuing on their first line treatment and receive DTG+RPV for 48 weeks. All participants will then be followed up for a further 30 days. Participants will be recruited from sites across Europe, and randomised onto either arm of the study. After randomisation, participants will attend approximately 10 visits over the course of two years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 140
• Est. completion date: October 27, 2022
• Est. primary completion date: November 15, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria

Patient volunteers who meet all of the following criteria are eligible for this trial:

1. Is male or female aged 18 years or over.

2. Has documented HIV-1 infection

3. Is capable of giving informed consent

4. Is willing to comply with the protocol requirements

5. Virologically suppressed (plasma HIV-RNA <50 copies/mL for >24 weeks) and on a stable regimen.

6. Subjects are required to have a history of the K103N mutation (acquired or selected). Subjects who at any time have had the mutations 100I, 101E/P, 106A/M, 138K/G/Q, 181C/I/V, 188L, 190A/S/E/Q, 230L mutations are to be excluded. Other NNRTI region variants can be included. All PI and NRTI mutations are acceptable. Study sites may ask the coordinating centre for advice as required.

7. Subjects must have never failed INSTI (2 x VL >200 >2 weeks apart) but current regimen can include INSTI.

8. A female, may be eligible to enter and participate in the study if she:

a. is of non-child-bearing potential defined as either post-menopausal (12 months of spontaneous amenorrhea without an alternative medical cause and = 45 years of age) A high follicle stimulating hormone (FSH) level consistent with postmenopausal status may be used to confirm a post- menopausal state in women who are not using hormonal contraception) or hormonal replacement therapy at the discretion of the PI. However, in the absence of 12 months of amenorrhea, a single FSH measurement alone is insufficient. OR physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy or, OR is of child-bearing potential with a negative pregnancy test at Screening (& baseline visit) and agrees to use one of the following methods of contraception to avoid pregnancy: True abstinence from penile-vaginal intercourse from 2 weeks prior to administration of IP, throughout the study, and for at least 2 weeks after discontinuation of all study medications (When this is in line with the preferred and usual lifestyle of the subject.) (Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), and withdrawal are not acceptable methods of contraception. Any intrauterine device (IUD) with published data showing that the expected failure rate is <1% per year (not all IUDs meet this criterion, see Appendix 3 for an example listing of approved IUDs). Male partner sterilization confirmed prior to the female subject's entry into the study, and this male is the sole partner for that subject; Approved hormonal contraception (see appendix 4 for a listing of examples of approved hormonal contraception); Any other method with published data showing that the expected failure rate is <1% per year. Any contraceptive method must be used consistently and for at least 2 weeks after discontinuation of IP

9. If a heterosexually active male, he is using effective birth control methods and is willing to continue practising these birth control methods during the trial and until follow-up visit

10. Subjects currently receiving DTG or RPV, but not both, can be included. Exclusion criteria

Patients meeting 1 or more of the following criteria cannot be selected:

1. Infected with HIV-2

2. Detectable HIV-1 RNA at screening (HIV-1 RNA measurement >=50 c/mL).

3. Subjects requiring regular dosing doing with H2 or PPI antacid medications or a history of achlorhidria or drug known to interact with RPV or DTG.

4. Use of medications which are associated with Torsades de Pointes

5. Corrected QT interval (QTc [Bazett]) >450 milliseconds or QTc (Bazett) >480 milliseconds for participants with bundle branch block. The QTc is the QT interval corrected for heart rate according to Bazett's formula (QTcB).

6. Unstable health conditions (i.e. opportunistic infections, cancers, unstable liver disease etc).

7. Any evidence of an active Centers for Disease Control and Prevention Category C disease. Exceptions include cutaneous Kaposi's sarcoma not requiring systemic therapy and historic CD4+ lymphocyte counts of <200 cells/millimeter3.

8. History or presence of allergy to the study drugs or their components or drugs of their class;

9. Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia; other localized malignancies require agreement between the investigator and the Study medical monitor for inclusion of the subject prior to randomization;

10. Any pre-existing physical or mental condition which, in the opinion of the Investigator, may interfere with the subject's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participants. Subjects considered to pose a significant risk of suicide should be excluded.

11. Any condition which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the subject unable to take oral medication;

12. Using any concomitant therapy disallowed as per the reference safety information and product labelling for the study drugs. Specifically, co-administration with the

following medicinal products is not allowed:

• dofetilide or pilsicainide;
• fampridine (also known as dalfampridine);
• carbamazepine, oxcarbazepine, phenobarbital, phenytoin;
• rifampicin, rifapentine;
• proton pump inhibitors, such as omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole; - systemic dexamethasone, except as a single dose treatment;
• St John's wort (Hypericum perforatum).

13. Has acute viral hepatitis including, but not limited to, A, B, or C

14. Active hepatitis B/ Hep B non-immune subjects who have failed vaccination (antibody concentration < 10 international units). (If local practice does not include vaccination of low risk patients, then the patients without HBsAb are not excluded - this must be clearly documented in the medical records and eCRF). (Note: subjects can be re screened if they receive vaccination and subsequently meet eligibility criteria)

15. Evidence of Hepatitis B virus (HBV) infection based on the results of testing at Screening for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti-HBc), and Hepatitis B surface antibody (HBsAb) as follows: Participants positive for HBsAg are excluded; Participants positive for anti-HBc (negative HBsAg status) and negative for HBsAb are excluded. (if local practice does not include vaccination of low risk patients, then the patients without HBsAb are not excluded - this must be clearly documented in the medical records and eCRF. Note: Subject positive for anti-HBc (negative HBsAg status) and positive for HBsAb are immune to HBV and are not excluded.

16. Participants with an anticipated need for any Hepatitis C virus (HCV) therapy during the Early Switch Phase and for interferon-based therapy for HCV throughout the entire study period.

17. Any investigational drug within 30 days prior to the trial drug administration

18. Any evidence of viral resistance different to the one described in the inclusion criteria i.e. not meeting inclusion criteria or having different mutation at K103.

19. Dialysis or renal insufficiency (creatinine clearance < 50ml/min)

20. History of decompensated liver disease (Alanine aminotransferase (ALT) = 5 times the upper limit of normal (ULN), OR ALT =3xULN and bilirubin =1.5xULN (with >35% direct bilirubin)

21. Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)

22. Subjects with severe hepatic impairment (Class C) as determined by Child-Pugh classification (see appendix 4)

23. Opportunistic infection within 4 weeks prior to first dose of DTG plus RPV.

24. Clinical decision that a switch of antiretroviral therapy should be immediate

25. Screening blood result with any grade 3/4 toxicity according to Division of AIDS (DAIDS) grading scale, except: asymptomatic grade 3 glucose, amylase or lipid elevation or asymptomatic grade 4 triglyceride elevation (re-test allowed). or unconjugated hyperbilirubinaemia due to atanazavir exposure.

26. Any condition (including illicit drug use or alcohol abuse) or laboratory results which, in the investigator's opinion, interfere with assessments or completion of the trial.

27. Women planning pregnancy or who are pregnant or breast feeding. (NB: See section 6.12 Withdrawal Criteria for guidance if pregnancy does occur).

28. Females of childbearing potential and males must be willing to use a highly effective (acceptable effective contraceptive measures are only acceptable for IMP's with unlikely human teratogenicity / fetotoxicity in early pregnancy) method of contraception (hormonal method of birth control; true abstinence). Contraceptive methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered as highly effective birth control methods

(see Appendix 4). Such methods include:

• combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral intravaginal transdermal
• progesteron-only hormonal contraception associated with inhibition of ovulation oral injectable implantable
• Intrauterine device (IUD)
• Intrauterine hormone-releasing system ( IUS)
• bilateral tubal occlusion
• vasectomized partner
• true sexual abstinence (NB: See section 6.12 Withdrawal Criteria for guidance if pregnancy does occur).

29. Hypersensitivity to the active substances or to any of the excipients listed below:

List of excipients Tablet core • Mannitol (E421) • Magnesium stearate • Microcrystalline cellulose • Povidone (K29/32) • Sodium starch glycolate • Sodium stearyl fumarate • Lactose monohydrate • Croscarmellose sodium • Povidone (K30) • Polysorbate 20 • Silicified microcrystalline cellulose Tablet coating • Polyvinyl alcohol- part hydrolysed • Titanium dioxide (E171) • Macrogol • Talc • Iron oxide yellow (E172) Iron oxide red (E172)

Related Conditions & MeSH terms

• HIV-1-infection

Intervention

Drug:
• Dolutegravir & Rilpivirine 2 drug fixed dose combined therapy
Daily oral tablet

Locations

Country	Name	City	State
Belgium	Institute of Tropical Medecine	Antwerp
Belgium	St Pierre University Hospital	Brussels
France	CHU Hotel Dieu	Nantes
France	Hospital Saint Louis	Paris
France	Pitié-salpêtrière Hospital	Paris
Germany	University Bonn	Bonn
Germany	University Essen	Essen
Germany	Frankfurt University Hospital	Frankfurt
Germany	ICH Study Center, Hamburg	Hamburg
Italy	AAST delgi spedali civili di Brescia	Brescia
Italy	ASST FBF SACCO- I Division of Infectious Diseases 1	Milan
Italy	ASST FBF SACCO- I Division of Infectious Diseases 3	Milan
Italy	I.R.C.C.S San Raffaele Hospital	Milan
Italy	ASST GOM Niguarda Milano, Dep. Infectious Disease	Milano
Spain	Hospital General Universitario de Alicante	Alicante
Spain	Hospital Clínic de Barcelona	Barcelona
Spain	Hospital Universitari Vall d'Herbo	Barcelona
Spain	Infectious Diseases Unit Hospital de la Santa Creu i Sant Pau	Barcelona
Spain	Hospital General Universitario de Elche	Elche
Spain	Hospital Universitario La Paz, Madrid	Madrid
United Kingdom	Brighton & Sussex University NHS Trust	Brighton
United Kingdom	North Bristol NHS Trust, Southmead Hospital	Bristol
United Kingdom	Chelsea & Westminster Hospital	London
United Kingdom	Kings College Hospital London	London
United Kingdom	Mortimer Market Centre	London
United Kingdom	Queen Elizabeth Hospital	London
United Kingdom	Royal Free London NHS Foundation Trust	London
United Kingdom	St Marys Hospital	London
United Kingdom	The Royal London Hospital	London

Sponsors (2)

Lead Sponsor	Collaborator
NEAT ID Foundation	ViiV Healthcare

Countries where clinical trial is conducted

Belgium,  France,  Germany,  Italy,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Changed in HS CRP	HS CRP evaluation	week 24, 48 and 96
Other	Changed in CD4/CD8	CD4/CD8 evaluation	week 24, 48 and 96
Primary	Virological suppression	<50 copies/ml HIV RNA	48 weeks
Secondary	Proportion of participants with plasma HIV-1 RNA <50 c/mL	Plasma HIV-1 RNA <50 c/mL	week 24, 48 and 96
Secondary	Changes in blood cell counts	blood cell count evaluation	until week 96
Secondary	Changes in glucose levels	Glucose level evaluation	until week 96
Secondary	Changes in electrolyte levels	Electrolyte level evaluation	until week 96
Secondary	Changes in liver levels (bilirubin)	Liver level evaluation	until week 96
Secondary	Changes in liver levels (ALT and AST)	Liver level evaluation	until week 96
Secondary	Changes in liver levels (Urea)	Liver level evaluation	until week 96
Secondary	Changes in liver levels (HsCRP)	Liver level evaluation	until week 96
Secondary	Changes in renal markers (protein/creatinine ratio, albumin/creatinine ratio)	Renal markers evaluation	week 24, 48 and 96.
Secondary	Changes in renal markers (urine protein, urine creatinine)	Renal markers evaluation	week 24, 48 and 96.
Secondary	Changes in renal markers (blood creatinine)	Renal markers evaluation	week 24, 48 and 96.
Secondary	Changes in renal markers (eGFR)	Renal markers evaluation	week 24, 48 and 96.
Secondary	Changes in renal markers (blood albumin)	Renal markers evaluation	week 24, 48 and 96.
Secondary	Changes in renal markers (urine albumin)	Renal markers evaluation	week 24, 48 and 96.
Secondary	Changes in renal markers (Beta 2 Microglobulin)	Renal markers evaluation	week 24, 48 and 96.
Secondary	Changes in renal markers (potassium)	Renal markers evaluation	week 24, 48 and 96.
Secondary	Changes in renal markers (blood phosphate)	Renal markers evaluation	week 24, 48 and 96.
Secondary	Changes in renal markers (urine glucose)	Renal markers evaluation	week 24, 48 and 96.
Secondary	Changes in renal markers (urine phosphate)	Renal markers evaluation	week 24, 48 and 96.
Secondary	Changes in renal markers (creatinine phosphokinase)	Renal markers evaluation	week 24, 48 and 96.
Secondary	Changes in bone markers (ALP)	Bone markers evaluation	week 24, 48 and 96.
Secondary	Changes in bone markers (calcium)	Bone markers evaluation	week 24, 48 and 96.
Secondary	Changes in fasting lipids from baseline (total cholesterol, triglycerides)	Fasting lipids level evaluation	week 24, 48 and 96.
Secondary	Changes in fasting lipids from baseline (HDL, LDL)	Fasting lipids level evaluation	week 24, 48 and 96.
Secondary	Change from baseline in viral mutations for patients experiencing virological failure.	Mutations determined by resistance testing	until 96 weeks
Secondary	Changes in QoL	Questionnaire (EQ-5D-3L)	until week 96
Secondary	Changes in patient satisfaction	Questionnaire (HIVTSQ)	until week 96
Secondary	Number of participants with Adverse Events	Adverse Events reports (AEs, SAEs and treatment discontinuation)	until week 96
Secondary	Number of potential DDIs avoided	Comparing the drug interaction outcomes between antiretroviral therapy and co-medications before and after the switch by using the www.hiv-druginteractions.org/ website (within the same study arm and between study arms)	until week 96
Secondary	Virological suppression in individuals with previous NNRTIs virological failure and/or baseline transmitted resistance with the k103N resistance mutation, switching to DTG/RPV FDV	<200 copies/ml HIV RNA	week 24, 48, 96
Secondary	PK Analysis	plasma concentrations of DTG and RPV	Predpse, week 4(Experimental arm only), 48 (Experimental arm only) and 96.
Secondary	Changes in cell associated virus	PBMC Illumina MiSeq sequencing	week 48 and 96